全球抗感染剂市场规模、份额、趋势和成长分析报告（2026-2034年）

预计抗感染剂市场将从 2025 年的 1,572.5 亿美元成长到 2034 年的 1,866.1 亿美元，2026 年至 2034 年的复合年增长率为 1.92%。

随着感染疾病持续构成全球重大健康挑战，全球抗感染剂市场正不断扩大。抗感染剂，包括抗生素、抗病毒药物、抗真菌药物和抗寄生虫药物，在治疗多种感染疾病发挥至关重要的作用。感染疾病上升、全球旅行增加以及对新兴病原体的日益关注，是推动对有效抗感染疗法需求的主要因素。

市场成长也得益于医药研发的持续进步和创新药物製剂的开发。各国政府和医疗机构正加大对疾病监测系统和感染控制计画的投入，进一步推动了抗感染治疗需求的成长。此外，发展中地区医疗基础设施的扩建和药品可近性的提高，也使得这些必要的治疗能够惠及更多患者。

全球抗感染剂市场前景依然光明，主要得益于持续进行的下一代抗菌药物和联合治疗研发工作。生物技术创新和先进的药物发现平台有望加速新型抗感染药物的上市。此外，全球卫生安全和疫情应对日益受到重视，也可能刺激对感染疾病治疗方案的投资。随着医疗系统将有效控制感染作为优先事项，预计该市场将继续扩张。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球抗感染剂市场：按类型划分

• 市场分析、洞察与预测
• 抗菌药物（头孢菌素类、青霉素类、Fluoroquinolones、大环内酯类、碳青霉烯类等）
• 抗病毒药物
• 抗霉菌药物（Azole、Echinocandins、Polyenes等）

第五章：全球抗感染剂市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 肠外
• 局部的
• 其他的

第六章 全球抗感染剂市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 其他的

第七章 全球抗感染剂市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Pfizer Inc
  • Merck & Co. Inc
  • Gilead Sciences Inc
  • AbbVie
  • Bristol-Myers Squibb
  • AstraZeneca
  • Sandoz International GmbH
  • Bayer AG
  • Xellia Pharmaceuticals
  • Mankind Pharma
  • B. Braun SE
  • Boehringer Ingelheim

The Anti-Infective Agents Market size is expected to reach USD 186.61 Billion in 2034 from USD 157.25 Billion (2025) growing at a CAGR of 1.92% during 2026-2034.

The Global Anti-Infective Agents Market is expanding as infectious diseases continue to pose significant health challenges across the globe. Anti-infective agents, including antibiotics, antivirals, antifungals, and antiparasitic drugs, play a crucial role in treating a wide range of infections. Increasing incidences of infectious diseases, growing global travel, and rising concerns about emerging pathogens are major factors driving the demand for effective anti-infective therapies.

Market growth is also supported by continuous advancements in pharmaceutical research and the development of innovative drug formulations. Governments and healthcare organizations are investing in improved disease surveillance systems and infection control programs, which are contributing to increased demand for anti-infective treatments. Furthermore, the expansion of healthcare infrastructure and improved access to medicines in developing regions are enabling broader patient access to these essential therapies.

The future of the Global Anti-Infective Agents Market remains promising as ongoing research focuses on developing next-generation antimicrobial therapies and combination treatments. Biotechnology innovations and advanced drug discovery platforms are expected to accelerate the introduction of new anti-infective drugs. In addition, the growing emphasis on global health security and pandemic preparedness will likely drive investments in infectious disease treatment solutions. As healthcare systems prioritize effective infection management, the market is expected to continue expanding.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Antibacterials (Cephalosporins, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Others)
• Antivirals
• Antifungals (Azoles, Echinocandins, Polyenes, Others)

By Route of Administration

• Oral
• Parenteral
• Topical
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• Pfizer Inc, Merck Co Inc, Gilead Sciences Inc, AbbVie, BristolMyers Squibb, AstraZeneca, Sandoz International GmbH, Bayer AG, Xellia Pharmaceuticals, Mankind Pharma, B Braun SE, Boehringer Ingelheim
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTI-INFECTIVE AGENTS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Antibacterials (Cephalosporins, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Antivirals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Antifungals (Azoles, Echinocandins, Polyenes, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTI-INFECTIVE AGENTS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTI-INFECTIVE AGENTS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTI-INFECTIVE AGENTS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANTI-INFECTIVE AGENTS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Merck & Co. Inc
  • 9.2.3 Gilead Sciences Inc
  • 9.2.4 AbbVie
  • 9.2.5 Bristol-Myers Squibb
  • 9.2.6 AstraZeneca
  • 9.2.7 Sandoz International GmbH
  • 9.2.8 Bayer AG
  • 9.2.9 Xellia Pharmaceuticals
  • 9.2.10 Mankind Pharma
  • 9.2.11 B. Braun SE
  • 9.2.12 Boehringer Ingelheim